Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Virology ; 497: 136-145, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27467579

RESUMO

The CD27 and CD38 antigens are highly expressed on the plasmablast surface, and a massive plasmablast response has been described for dengue virus infection. Soluble CD27 and CD38 forms (sCD27 and sCD38, respectively) increase after immune activation. Here, we show increased sCD27 release in cultures of purified polyclonally stimulated B cells. T and B cells isolated from children with dengue spontaneously produced higher levels of sCD27 but not sCD38, compared with healthy children (P=0.03), and sCD27 levels positively correlated with plasmablast frequency in the cultures (rho=0.58, P=0.01). Children with dengue had higher plasma levels of sCD27 and sCD38 than healthy children, which decreased during convalescence. Plasma sCD27 was higher in severe than with mild dengue, but the opposite was observed for sCD38. These findings support a potential new role for B cells in dengue pathogenesis, and sCD27 and sCD38 are novel biomarkers associated with clinical outcome during dengue virus infection.


Assuntos
Linfócitos B/imunologia , Linfócitos B/metabolismo , Vírus da Dengue/imunologia , Dengue/imunologia , Dengue/virologia , Membro 7 da Superfamília de Receptores de Fatores de Necrose Tumoral/sangue , ADP-Ribosil Ciclase 1/sangue , Adolescente , Linfócitos B/virologia , Biomarcadores , Estudos de Casos e Controles , Criança , Pré-Escolar , Dengue/diagnóstico , Dengue/epidemiologia , Vírus da Dengue/classificação , Feminino , Humanos , Imunofenotipagem , Ativação Linfocitária/imunologia , Masculino , Fenótipo , Sorogrupo , Índice de Gravidade de Doença
2.
Rev Invest Clin ; 64(1): 17-24, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22690525

RESUMO

OBJECTIVE: To evaluate the impact of different prognostic factors that has been suggested to be useful in predicting the survival of patients with multiple myeloma (MM). MATERIALS AND METHODS: A longitudinal prospective study was conducted on 24 adult Mexican patients diagnosed with primary MM. The levels of expression of CD38, CD138 and cyclin D1 were analyzed in plasma cells (PCs) from patients and mononuclear cells from healthy donors. Serum levels of lactate dehydrogenase, creatinine, calcium, beta2 microglobulin and interleukin-6 (IL-6) as well as hemoglobin and platelet count were taken into consideration. RESULTS; CD138 and cyclin D1 levels in absolute numbers were significantly overexpressed in malignant PCs. A positive correlation was noted between cyclin D1 and CD38 expression levels in malignant PCs. IL-6 and serum calcium were also positively correlated in MM patients. Cyclin D1 overexpression was not associated with better overall survival (OS). Normal calcium levels were associated with better overall survival (OS). Serum calcium was the only variable correlating with better OS in Cox regression analysis. CONCLUSION: Serum calcium is an independent prognostic factor of OS in a population of Mexican patients with MM.


Assuntos
Cálcio/sangue , Mieloma Múltiplo/sangue , ADP-Ribosil Ciclase 1/sangue , Adulto , Idoso , Biomarcadores/sangue , Biomarcadores Tumorais/sangue , Medula Óssea/patologia , Creatinina/sangue , Ciclina D1/sangue , Feminino , Hemoglobinas/análise , Humanos , Interleucina-6/sangue , Estimativa de Kaplan-Meier , L-Lactato Desidrogenase/sangue , Masculino , Glicoproteínas de Membrana/sangue , México/epidemiologia , Pessoa de Meia-Idade , Mieloma Múltiplo/mortalidade , Mieloma Múltiplo/patologia , Proteínas de Neoplasias/sangue , Contagem de Plaquetas , Prognóstico , Modelos de Riscos Proporcionais , Estudos Prospectivos , Análise de Sobrevida , Microglobulina beta-2/análise
3.
Hematology ; 13(1): 24-7, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18534062

RESUMO

We studied the clinical impact of CD38 expression in 226 chronic lymphocytic leukemia patients (CLL) at disease presentation and during follow up to determine its prognostic significance, progression free survival (PFS) and overall survival (OS), and to verify whether this parameter changed over time. Various patients' characteristics were studied including gender, Rai and Binet stages, immunoglobulin light chain expression, lymphocyte doubling time and CD38 expression. After a median follow up of 53 months (range 6-282), 62% CD38 positive(+) patients required therapy. PFS and OS at 84 months were significantly lower for CD38(+) patients: 20 and 71% respectively, compared to CD38 negative(-): 70 and 96%. At multivariate analysis CD38(+) showed to be the best factor for predicting progression: HR 3.3, 95%CI 2.10-5.14, p = 0.000. Its expression did not change in 98% re-evaluated patients. We confirm that CD38(+) is a stable parameter for the identification of CLL patients with a more aggressive disease course.


Assuntos
ADP-Ribosil Ciclase 1/sangue , Leucemia Linfocítica Crônica de Células B/imunologia , Subpopulações de Linfócitos/classificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Estudos de Coortes , Progressão da Doença , Intervalo Livre de Doença , Feminino , Humanos , Leucemia Linfocítica Crônica de Células B/classificação , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA